{"id":4152,"date":"2026-06-15T10:53:52","date_gmt":"2026-06-15T10:53:52","guid":{"rendered":"https:\/\/www.sygnaturediscovery.com\/poster\/polq-inhibitor-ai-drug-discovery-oncology\/"},"modified":"2026-06-15T10:53:53","modified_gmt":"2026-06-15T10:53:53","slug":"polq-inhibitor-ai-drug-discovery-oncology","status":"publish","type":"poster","link":"https:\/\/www.sygnaturediscovery.com\/fr\/poster\/polq-inhibitor-ai-drug-discovery-oncology\/","title":{"rendered":"Combining Artificial Intelligence and Human Expertise in Pursuit of Novel PolQ Inhibitors"},"content":{"rendered":"<p><span style=\"font-family: arial, helvetica, sans-serif;\">Sygnature Discovery, in collaboration with Iktos, presents a poster outlining the use of AI drug discovery to design and optimize a novel scaffold of PolQ inhibitors. Through iterative generative design, medicinal chemistry refinement and early ADME assessment, the project highlights how AI and expert-driven design can work together to accelerate discovery of precision oncology therapies.<\/span><\/p>\n<h3><span style=\"font-family: arial, helvetica, sans-serif;\">Study Highlights:<\/span><\/h3>\n<ul>\n<li><span style=\"font-family: arial, helvetica, sans-serif;\">Generative AI for scaffold identification<\/span><\/li>\n<li><span style=\"font-family: arial, helvetica, sans-serif;\">Potency improvement through medicinal chemistry<\/span><\/li>\n<li><span style=\"font-family: arial, helvetica, sans-serif;\">Favourable early ADME profiles<\/span><\/li>\n<li><span style=\"font-family: arial, helvetica, sans-serif;\">Precision oncology approach via DDR targeting<\/span><\/li>\n<\/ul>\n<h3><span style=\"font-family: arial, helvetica, sans-serif;\">Advancing PolQ Inhibitor Design Through AI Drug Discovery<\/span><\/h3>\n<p><span style=\"font-family: arial, helvetica, sans-serif;\">This study demonstrates how PolQ inhibitors can be designed and optimized rapidly using AI drug discovery methods combined with expert medicinal chemistry. The resulting compounds show promise for further preclinical profiling in DNA damage response-driven oncology strategies.<\/span><\/p>\n<h2><span style=\"font-family: arial, helvetica, sans-serif;\">Explore out AI-Integrated Discovery Chemistry Expertise<\/span><\/h2>\n<p><span style=\"font-family: arial, helvetica, sans-serif;\">Sygnature Discovery supports AI-guided small molecule discovery through integrated <a href=\"https:\/\/www.sygnaturediscovery.com\/drug-discovery\/chemistry\/\">medicinal chemistry<\/a>,<a href=\"https:\/\/www.sygnaturediscovery.com\/drug-discovery\/integrated-drug-discovery\/targeted-protein-degradation\/\"> targeted protein degradation and DDR biology<\/a>, and <a href=\"https:\/\/www.sygnaturediscovery.com\/drug-discovery\/dmpk-and-physical-sciences\/\">ADME profiling<\/a>. Whether using generative AI tools, structural modelling or traditional screening, our teams accelerate hit-to-lead optimization and compound profiling.<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"","protected":false},"featured_media":17490,"template":"","category":[710,679,683,697,691,719],"class_list":["post-4152","poster","type-poster","status-publish","has-post-thumbnail","hentry","category-biochemical-assays","category-computer-aided-drug-design","category-dmpk","category-generative-ai-and-machine-learning","category-hit-to-lead","category-physicochemical-profiling"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>AI-Designed PolQ Inhibitors for DDR Oncology | Sygnature<\/title>\n<meta name=\"description\" content=\"How Sygnature and Iktos combined generative AI and medicinal chemistry to design a novel PolQ inhibitor scaffold with favorable early ADME. Learn more.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.sygnaturediscovery.com\/fr\/poster\/polq-inhibitor-ai-drug-discovery-oncology\/\" \/>\n<meta property=\"og:locale\" content=\"fr_CA\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AI-Designed PolQ Inhibitors for DDR Oncology | Sygnature\" \/>\n<meta property=\"og:description\" content=\"How Sygnature and Iktos combined generative AI and medicinal chemistry to design a novel PolQ inhibitor scaffold with favorable early ADME. Learn more.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.sygnaturediscovery.com\/fr\/poster\/polq-inhibitor-ai-drug-discovery-oncology\/\" \/>\n<meta property=\"og:site_name\" content=\"Sygnature\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-15T10:53:53+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2026\/02\/sygnature-hit-to-lead-team-collaboration-scaled.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1707\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Estimation du temps de lecture\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/poster\\\/polq-inhibitor-ai-drug-discovery-oncology\\\/\",\"url\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/poster\\\/polq-inhibitor-ai-drug-discovery-oncology\\\/\",\"name\":\"AI-Designed PolQ Inhibitors for DDR Oncology | Sygnature\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/poster\\\/polq-inhibitor-ai-drug-discovery-oncology\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/poster\\\/polq-inhibitor-ai-drug-discovery-oncology\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/Combining-artificial-intelligence-and-human-expertise-in-pursuit-of-novel-PolQ-inhibitors-pdf.jpg\",\"datePublished\":\"2026-06-15T10:53:52+00:00\",\"dateModified\":\"2026-06-15T10:53:53+00:00\",\"description\":\"How Sygnature and Iktos combined generative AI and medicinal chemistry to design a novel PolQ inhibitor scaffold with favorable early ADME. Learn more.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/poster\\\/polq-inhibitor-ai-drug-discovery-oncology\\\/#breadcrumb\"},\"inLanguage\":\"fr-CA\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/poster\\\/polq-inhibitor-ai-drug-discovery-oncology\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-CA\",\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/poster\\\/polq-inhibitor-ai-drug-discovery-oncology\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/Combining-artificial-intelligence-and-human-expertise-in-pursuit-of-novel-PolQ-inhibitors-pdf.jpg\",\"contentUrl\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/Combining-artificial-intelligence-and-human-expertise-in-pursuit-of-novel-PolQ-inhibitors-pdf.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/poster\\\/polq-inhibitor-ai-drug-discovery-oncology\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Combining Artificial Intelligence and Human Expertise in Pursuit of Novel PolQ Inhibitors\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/\",\"name\":\"Sygnature Discovery\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/#organization\"},\"alternateName\":\"Sygnature\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-CA\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/#organization\",\"name\":\"Sygnature Discovery\",\"alternateName\":\"Sygnature\",\"url\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-CA\",\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/Logo.svg\",\"contentUrl\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/Logo.svg\",\"width\":1,\"height\":1,\"caption\":\"Sygnature Discovery\"},\"image\":{\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.youtube.com\\\/@sygnature.discovery\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/sygnature-discovery\\\/\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"AI-Designed PolQ Inhibitors for DDR Oncology | Sygnature","description":"How Sygnature and Iktos combined generative AI and medicinal chemistry to design a novel PolQ inhibitor scaffold with favorable early ADME. Learn more.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.sygnaturediscovery.com\/fr\/poster\/polq-inhibitor-ai-drug-discovery-oncology\/","og_locale":"fr_CA","og_type":"article","og_title":"AI-Designed PolQ Inhibitors for DDR Oncology | Sygnature","og_description":"How Sygnature and Iktos combined generative AI and medicinal chemistry to design a novel PolQ inhibitor scaffold with favorable early ADME. Learn more.","og_url":"https:\/\/www.sygnaturediscovery.com\/fr\/poster\/polq-inhibitor-ai-drug-discovery-oncology\/","og_site_name":"Sygnature","article_modified_time":"2026-06-15T10:53:53+00:00","og_image":[{"width":2560,"height":1707,"url":"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2026\/02\/sygnature-hit-to-lead-team-collaboration-scaled.webp","type":"image\/webp"}],"twitter_card":"summary_large_image","twitter_misc":{"Estimation du temps de lecture":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.sygnaturediscovery.com\/fr\/poster\/polq-inhibitor-ai-drug-discovery-oncology\/","url":"https:\/\/www.sygnaturediscovery.com\/fr\/poster\/polq-inhibitor-ai-drug-discovery-oncology\/","name":"AI-Designed PolQ Inhibitors for DDR Oncology | Sygnature","isPartOf":{"@id":"https:\/\/www.sygnaturediscovery.com\/fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.sygnaturediscovery.com\/fr\/poster\/polq-inhibitor-ai-drug-discovery-oncology\/#primaryimage"},"image":{"@id":"https:\/\/www.sygnaturediscovery.com\/fr\/poster\/polq-inhibitor-ai-drug-discovery-oncology\/#primaryimage"},"thumbnailUrl":"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2025\/04\/Combining-artificial-intelligence-and-human-expertise-in-pursuit-of-novel-PolQ-inhibitors-pdf.jpg","datePublished":"2026-06-15T10:53:52+00:00","dateModified":"2026-06-15T10:53:53+00:00","description":"How Sygnature and Iktos combined generative AI and medicinal chemistry to design a novel PolQ inhibitor scaffold with favorable early ADME. Learn more.","breadcrumb":{"@id":"https:\/\/www.sygnaturediscovery.com\/fr\/poster\/polq-inhibitor-ai-drug-discovery-oncology\/#breadcrumb"},"inLanguage":"fr-CA","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.sygnaturediscovery.com\/fr\/poster\/polq-inhibitor-ai-drug-discovery-oncology\/"]}]},{"@type":"ImageObject","inLanguage":"fr-CA","@id":"https:\/\/www.sygnaturediscovery.com\/fr\/poster\/polq-inhibitor-ai-drug-discovery-oncology\/#primaryimage","url":"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2025\/04\/Combining-artificial-intelligence-and-human-expertise-in-pursuit-of-novel-PolQ-inhibitors-pdf.jpg","contentUrl":"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2025\/04\/Combining-artificial-intelligence-and-human-expertise-in-pursuit-of-novel-PolQ-inhibitors-pdf.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.sygnaturediscovery.com\/fr\/poster\/polq-inhibitor-ai-drug-discovery-oncology\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.sygnaturediscovery.com\/fr\/"},{"@type":"ListItem","position":2,"name":"Combining Artificial Intelligence and Human Expertise in Pursuit of Novel PolQ Inhibitors"}]},{"@type":"WebSite","@id":"https:\/\/www.sygnaturediscovery.com\/fr\/#website","url":"https:\/\/www.sygnaturediscovery.com\/fr\/","name":"Sygnature Discovery","description":"","publisher":{"@id":"https:\/\/www.sygnaturediscovery.com\/fr\/#organization"},"alternateName":"Sygnature","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.sygnaturediscovery.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-CA"},{"@type":"Organization","@id":"https:\/\/www.sygnaturediscovery.com\/fr\/#organization","name":"Sygnature Discovery","alternateName":"Sygnature","url":"https:\/\/www.sygnaturediscovery.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-CA","@id":"https:\/\/www.sygnaturediscovery.com\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2025\/11\/Logo.svg","contentUrl":"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2025\/11\/Logo.svg","width":1,"height":1,"caption":"Sygnature Discovery"},"image":{"@id":"https:\/\/www.sygnaturediscovery.com\/fr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.youtube.com\/@sygnature.discovery","https:\/\/www.linkedin.com\/company\/sygnature-discovery\/"]}]}},"_links":{"self":[{"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/poster\/4152","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/poster"}],"about":[{"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/types\/poster"}],"version-history":[{"count":0,"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/poster\/4152\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/media\/17490"}],"wp:attachment":[{"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/media?parent=4152"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/category?post=4152"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}